香港聯合交易所有限公司與證券及期貨事務監察委員會對本申請版本的內容概不負責，對其準確性或完整 性亦不發表任何聲明，並明確表示概不就因本申請版本全部或任何部分內容而產生或因倚賴該等內容而引 致的任何損失承擔任何責任。 四川百利天恒藥業股份有限公司 （「本公司」） （於中華人民共和國註冊成立的股份有限公司） 的申請版本 警告 本申請版本乃根據香港聯合交易所有限公司（「聯交所」）及證券及期貨事務監察委員會（「證監 會」）的要求而刊發，僅用作提供資訊予香港公眾人士。 本申請版本為草擬本，其內所載資料並不完整，亦可能會作出重大變動。您閱覽本文件，即代 表您知悉、接納並向本公司、其聯席保薦人、整體協調人、顧問或包銷團成員表示同意： 倘於適當時候向香港公眾人士提出要約或邀請，準投資者務請僅依據呈交香港公司註冊處處長 註冊的本公司招股章程作出投資決定；有關文本將於發售期內向公眾刊發。 (a) 本文件僅為向香港公眾人士提供有關本公司的資料，概無任何其他目的。投資者不應根 據本文件中的資料作出任何投資決定； (b) 在聯交所網站登載本文件或其補充、修訂或更換附頁，並不引起本公司、其聯席保薦 人、整體協調人、顧問或包銷團成員須在香 ...

Core Insights - WuXi Biologics (02269) reported a record high of 86 new comprehensive projects signed in the first half of 2025, increasing the total number of comprehensive projects to 864, solidifying its leading position in the industry with one of the largest complex biologics product lines [1] - The company has raised its full-year revenue guidance for 2025 to a growth range of 14%-16% due to rapid performance growth [1] Project Performance - As of June 30, 2025, WuXi Biologics had 67 clinical phase III and 24 commercial production projects on its integrated platform, with revenue increasing by 24.9% year-on-year [1] - The research services have empowered over 50 molecular projects, with potential milestone payments and sales royalties expected to significantly enhance the company's long-term profit growth [1] Clinical Development - A molecule developed for GSK has entered the clinical stage, marking the fourth TCE project enabled by WuXi Biologics to reach this phase [1] Order Backlog - The total amount of unfulfilled orders for WuXi Biologics exceeds $20.34 billion, with unfulfilled orders over the past three years growing to $4.21 billion, indicating a substantial expected revenue increase in the near term [1]

Core Viewpoint - Tianjing Bio (IMAB) has shown significant financial growth, with a notable increase in revenue and a focus on innovative biopharmaceuticals in the oncology and autoimmune sectors [1][2]. Financial Performance - As of December 31, 2023, Tianjing Bio reported total revenue of 27.644 million RMB, representing a year-on-year growth of 112.48% [1]. - The company's net profit attributable to shareholders was -1.466 billion RMB, which reflects a year-on-year increase of 41.54% [1]. Company Overview - Tianjing Bio is an offshore holding company that operates through its domestic subsidiary, focusing on developing innovative biopharmaceuticals with "first-in-class" and "best-in-class" potential [2]. - The company's mission is to create groundbreaking biopharmaceuticals that address unmet clinical needs and improve the quality of life for patients globally [2]. - Tianjing Bio aims to establish itself as a leading biopharmaceutical company rooted in China and oriented towards global markets [2].

Core Viewpoint - Zhuhai Tenomab Pharmaceutical Co., Ltd. (Tenomab) has applied for a change in its listing review status on the Shanghai Stock Exchange's Sci-Tech Innovation Board to "inquired," with plans to raise 1.5 billion RMB [1] Company Overview - Tenomab is an innovative biopharmaceutical company focused on blood product alternatives, equipped with proprietary technology platforms for monoclonal antibody development and production [1] - The company has developed several core technology platforms, including HitmAb® for high-throughput human monoclonal antibody research and a CHO-GS cell platform for efficient antibody expression [1] Key Products - The core product, TNM002 (Stadotamab Injection), is a first-in-class recombinant human monoclonal antibody for tetanus prevention, expected to be approved in China by February 2025 and recognized as a breakthrough therapy by the CDE [2] - Another key product, TNM001, is a potential third global and first domestic long-acting monoclonal antibody for RSV prevention in infants, currently undergoing Phase III clinical trials [2] Fundraising and Investment Plans - The total investment for the new drug development project is approximately 836.5 million RMB, with 830 million RMB planned to be raised from this issuance [3] - The antibody production base expansion project has a total investment of about 381.37 million RMB, with 330 million RMB from the raised funds [3] - The company plans to allocate all raised funds to its main business projects and operational needs [2][3] Financial Performance - In 2022, the company reported revenues of approximately 4.34 million RMB, with projected revenues of 15.06 million RMB in 2024 and 1.69 million RMB in Q1 2025 [3] - The net profit for 2022 was approximately -429 million RMB, with projected losses of -446 million RMB in 2023 and -515 million RMB in 2024 [3] - As of March 31, 2025, total assets are reported at approximately 1.13 billion RMB, with a debt-to-asset ratio of 56.48% [4]

四川百利天恒药业股份有限公司 上市公告书 股票简称：百利天恒 股票代码：688506 四川百利天恒药业股份有限公司 上市公告书 特别提示 四川百利天恒药业股份有限公司（以下简称"百利天恒"、"发行人"、"公 司"或"本公司"）股票将于 2023 年 1 月 6 日在上海证券交易所科创板上市。 本公司提醒投资者应充分了解股票市场风险及本公司披露的风险因素，在新股上 市初期切忌盲目跟风"炒新"，应当审慎决策、理性投资。 四川百利天恒药业股份有限公司 （成都市温江区成都海峡两岸科技产业园百利路 161 号一幢一号） 首次公开发行股票科创板上市公告书 保荐机构（主承销商） （广东省深圳市福田区福田街道福华一路 119 号安信金融大厦） 二〇二三年一月五日 1 四川百利天恒药业股份有限公司 上市公告书 第一节 重要声明与提示 一、重要声明 本公司及全体董事、监事、高级管理人员保证上市公告书所披露信息的真实、 准确、完整，承诺上市公告书不存在虚假记载、误导性陈述或重大遗漏，并依法 承担法律责任。 上海证券交易所（以下简称"上交所"）、有关政府机关对本公司股票上市 及有关事项的意见，均不表明对本公司的任何保证。 本 公 司 ...